EGFR (d746-750)

EGFR · Variant type: unknown

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Osimertinib	98.9%	1.1%	97.24
2	Neratinib	98.5%	1.5%	93.18
3	Lazertinib	98.5%	1.5%	97.47
4	Pralsetinib	98.4%	1.6%	93.43
5	Mobocertinib	98.4%	1.6%	97.22
6	Afatinib	97.8%	2.2%	98.50
7	Gefitinib	97.5%	2.5%	99.25
8	Erlotinib	96.5%	3.5%	99.75
9	Dacomitinib	96.2%	3.8%	97.99
10	Canertinib	95.8%	4.2%	96.49
11	Bosutinib	95.6%	4.4%	87.22
12	Vandetanib	95.2%	4.8%	95.74
13	Capmatinib	93.8%	6.2%	99.75
14	Brigatinib	91.4%	8.6%	82.96
15	Pacritinib	91.0%	9.0%	88.64
16	Dasatinib	90.7%	9.3%	87.97
17	Ibrutinib	89.5%	10.5%	94.74
18	Fostamatinib	86.0%	14.0%	96.74
19	Ponatinib	82.5%	17.5%	78.23
20	Alpelisib	74.3%	25.7%	97.22
21	Gilteritinib	62.6%	37.4%	88.97
22	Alectinib	61.5%	38.5%	95.49
23	Lapatinib	42.5%	57.5%	99.25
24	Defactinib	42.2%	57.8%	92.68
25	Ceritinib	38.5%	61.5%	95.44

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Osimertinib	98.9%	99.1%	-0.2%
Neratinib	98.5%	100.0%	-1.5%
Lazertinib	98.5%	100.0%	-1.5%
Pralsetinib	98.4%	99.1%	-0.7%
Mobocertinib	98.4%	100.0%	-1.6%
Afatinib	97.8%	100.0%	-2.2%
Gefitinib	97.5%	99.9%	-2.4%
Erlotinib	96.5%	99.4%	-3.0%
Dacomitinib	96.2%	99.8%	-3.6%
Canertinib	95.8%	98.4%	-2.7%
Bosutinib	95.6%	99.3%	-3.7%
Vandetanib	95.2%	99.3%	-4.2%
Capmatinib	93.8%	—	—
Brigatinib	91.4%	98.5%	-7.1%
Pacritinib	91.0%	—	—
Dasatinib	90.7%	97.9%	-7.2%
Ibrutinib	89.5%	99.3%	-9.8%
Fostamatinib	86.0%	97.8%	-11.7%
Ponatinib	82.5%	—	—
Alpelisib	74.3%	—	—
Gilteritinib	62.6%	91.0%	-28.4%
Alectinib	61.5%	—	—
Lapatinib	42.5%	99.2%	-56.7%
Defactinib	42.2%	94.6%	-52.4%
Ceritinib	38.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 36.9ms